Vantage logo

Amarin enters the home stretch

After an overwhelmingly positive adcom, the outstanding question around Vascepa is just how big the product might become.

Vantage logo

Neptune leaves Astra at sea

The Neptune lung cancer study fails, denting yet further Astrazeneca and Bristol-Myers Squibb’s chances of challenging Merck & Co’s Keytruda on the basis of tumour…